BFNH

BioForce Nanosciences Holdings, Inc.

QUARTERLY INFORMATION FOR NINE MONTH ENDING SEPTEMBER 30, 2017

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

BIOFORCE NANOSCIENCES HOLDINGS, INC.

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 2020 General Booth Blvd, Unit 230 Virginia Beach, VA 23454
Address 2: 3419 Virginia Beach Blvd, Unit 252, Virginia Beach, VA 23452 (Mailing Address)
Phone: 7573066090
Email: rich@yesinternational.com
Website(s): pending

IR Contact
Address 1: YES INTERNATIONAL
Address 2: 3419 Virginia Beach Blvd, Unit 252, Virginia Beach, VA 23452
Phone: 7573066090
Email: yes@yesinternational.com
Website(s): www.yesinternational.com

3) Security Information

Trading Symbol: BFNH
Exact title and class of securities outstanding: Common Stock, Par Value $.001
CUSIP: 09064C107
Par or Stated Value: .001
Total shares authorized: 100,000,000 as of: 10/31/2000
Total shares outstanding: 76,295,171 as of: 10/31/2017

Additional class of securities (if necessary):
Trading Symbol: None
Exact title and class of securities outstanding: Preferred Class 'A'
CUSIP: none
Par or Stated Value: .001
Total shares authorized: 10,000,000 as of: 01/10/2006
Total shares outstanding: -0- as of: 10/31/2017

Transfer Agent
Name: Transfer Online
Address 1: 512 SE Salmon Street, Portland OR 97124
Address 2: www.transferonline.com
Phone: 503-227-6870
Is the Transfer Agent registered under the Exchange Act?* Yes: X No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

NONE

Describe any trading suspension orders issued by the SEC in the past 12 months.

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

- On September 17, 2017 the Company issued to Mr. Steve Lepkowski 188,000 Rule 144 shares at $0.06 per share in lieu of cash on invoices totaling $11,280 owed to his Company BodyAlign, LLC based on a board approved settlement agreement.

-On January 26, 2017, the Company issued to Mr. Ferguson his, in lieu of cash compensation, 20 Million shares of Rule 144 restrictive common stock at $0.01 per share for Officer and Chairman duties.

-On January 26, 2017, the Company's board approved the issuance of 10 Million share of Rule 144 restrictive common stock at $0.01 per share to Trade Exchange International, Inc. for consulting and marketing services.

-On January 26, 2017, the Company's board approved the issuance of 10 Million shares of Rule 144 restrictive common stock at $0.01 per share to TJJR Enterprises, Inc. for consulting and marketing services.

As of October 31, 2017, the Company has 76,295,171 Common Shares outstanding.

B. Any jurisdictions where the offering was registered or qualified;

N/A

C. The number of shares offered;

N/A

D. The number of shares sold;

N/A

E. The price at which the shares were offered, and the amount actually paid to the issuer;

N/A

F. The trading status of the shares; and

N/A

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

- On September 17, 2017, the Company issued to Mr. Steve Lepkowski 188,000 Rule 144 shares at $0.06 per share in lieu of cash on invoices totaling $11,280 owed to his Company BodyAlign, LLC based on a board approved settlement agreement.

-On January 26, 2017, the Company issued to Mr. Ferguson his, in lieu of cash compensation, 20 Million shares of Rule 144-restrictive common stock at $0.01 per share for Officer and Chairman duties.

-On January 26, 2017, the Company's board approved the issuance of 10 Million share of Rule 144-restrictive common stock at $0.01 per share to Trade Exchange International, Inc. for consulting and marketing services.

-On January 26, 2017, the Company's board approved the issuance of 10 Million shares of Rule 144-restrictive common stock at $0.01 per share to TJJR Enterprises, Inc. for consulting and marketing services.

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

A. Balance sheet;
B. Statement of income;
C. Statement of cash flows;
D. Financial notes; and
E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otciq.com in the field below.

<u>Quarterly Financial Statements for the Periods ending September 30, 2017 are filed as a separate document.</u>**

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

<u>The Company owns, develops, acquires, and/or licenses medical technological applications as they relate to the conventional and holistic health care industries.</u>

B. Date and State (or Jurisdiction) of Incorporation:

NEVADA: December 10, 1999

C. the issuer's primary and secondary SIC Codes;

5122; 5149

D. the issuer's fiscal year end date;

12/31

E. principal products or services, and their markets;

Vitamins and Healthy Diet Programs for individuals, health food stores and nutritional education facilities

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company's Office is located at 2020 General Booth Blvd., Unit 230,Virginia Beach, VA., 23454. The Director, Secretary and Acting CFO, Richard Kaiser is providing a 500 sq. ft of office space for the Company at no charge, including phone and internet services.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Merle Ferguson, Chairman, President; Richard Kaiser, Director, Secretary and Acting CFO

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

NONE

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   NONE

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   NONE

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   NONE

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Name: Robert Wright
Firm: Law Office of Robert W. Wright
Address 1: 716 Castro Street
Address 2: Solana Beach, CA 92075
Phone: 858-353-6591

Accountant or Auditor
Name: CS&S Enterprises
Firm: CS&S Enterprises
Address 1: 5840 West Craig Road
Address 2: Suite 120, Las Vegas, NV 89130

Investor Relations Consultant
Name:
Firm: YES INTERNATIONAL
Address 1: 3419 Virginia Beach Blvd, Unit 252, Virginia Beach, VA 23452
Phone: 757-306-6090
Email: yes@yesinternational.com

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Merle Ferguson certify that:

1. I have reviewed this document which contains financial statements for Quarter ending September 30, 2017 of BioForce Nanosciences Holdings, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

10/31/2017

/s/ Merle Ferguson
(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Chairman,CEO & President